Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells[1].
Amivantamab (JNJ-61186372)(0.05-1 mg/mL) 导致 Ba/F3 细胞活力显着且剂量依赖性降低，EGFR 下游信号通路磷酸化 EGFR (pEGFR)、磷酸化 AKT (pAKT)、磷酸化 ERK (pERK) 和磷酸化 S6 (pS6) 也显着降低[2]。
Amivantamab (JNJ-61186372) (i.p, 30 mg/kg, twice a week, 15 days) 可以有效减小雌性无胸腺 BALB-c/nu 小鼠肿瘤体积，具有体内抗肿瘤作用[2]。
[1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402.
[2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models ofEGFRExon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.